Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for proteinuria reduction in non-diabetic chronic kidney disease
IRCT20211104052965N1Phase 4Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in chronic kidney disease (CKD) comparing Empagliflozin with Placebo (2 arms). Primary endpoints: Reduction in microalbuminuria from baseline, Incident microalbuminuria and 1 more. Started Sep 2022; status: completed.
02
Drugs
empagliflozin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on IRCT20211104052965N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20211104052965N1.